Romosozumab mitigates progression from radiological to symptomatic adjacent-level fractures compared to teriparatide
Authors' conclusion
RM was associated with a lower incidence of symptomatic adjacent-level SVCF compared to TP. This difference was not attributed to a lower incidence of radiological SVCF, but rather to a reduced conversion rate from radiological to symptomatic fractures requiring surgical intervention.
Study context
- Population
- Patients with osteoporotic vertebral compression fracture treated with cement augmentation (Taipei Medical University Clinical Research Database (TMUCRD) and Taipei Medical University Hospital (TMUH) cohorts)TMUCRD cohort
- Participants
- 813 patients
- Exposure
- Romosozumab vs teriparatide after cement augmentation for osteoporotic vertebral compression fracture
- Outcome
- Symptomatic SVCF, defined as requiring subsequent vertebral cement augmentation
- Follow-up
- 2 years
Methodological detailsmulticentre database cohort, hospital-based cohort
- Multicentre database cohort
- Hospital-based cohort
Main finding
As reported in the abstract
Symptomatic SVCF incidence (TMUCRD cohort)
P = 0.003
Observational data: associations, not effects.
Further findings
Operation conversion rate, radiological to symptomatic adjacent-level SVCF (TMUH cohort)
P = 0.03
Radiological adjacent-level SVCF incidence and postoperative analgesic consumption (TMUH cohort)
- Comparable between groups
Original publication
Romosozumab mitigates progression from radiological to symptomatic adjacent-level fractures compared to teriparatide. Osteoporos Int. Published 16 December 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →